Aurinia Pharmaceuticals Inc.

Background Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis ( LN ). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor ( BAFF ) and a proliferation-inducing ligand ( APRIL ) for the potential treatment of autoimmune diseases. Net Product Sales Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the United States ( U.S. ), and Aurinia sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. ( Otsuka ), for the European and Japanese market. For the year ended December 31, 2025, net product sales were $271.3 million, up 25% compared to $216.2 million in 2024. LUPKYNIS Net Product Sales Cash Flows from Operating Activities For the year ended December 31, 2025, cash flows from operating activities were $135.7 million, up 206% compared to $44.4 million in 2024. Cash Position As of December 31, 2025, Aurinia had cash, cash equivalents, restricted cash and investments of $398.0 million, compared to $358.5 million at December 31, 2024. For the year ended December 31, 2025, the Company repurchased 12.2 million of its common shares for $98.2 million.